Navigating the Intersection of FDA Oversight and Patent Law for AI-Enabled Health Care Technologies

Strategic Insights -

As AI-enabled medical devices and diagnostic tools continue to transform the health care industry, innovators face a dual challenge: ensuring FDA oversight for patient safety while navigating patent law hurdles that govern inventorship, subject matter eligibility, and the adaptability of AI technologies. This requires a deep understanding of the FDA's regulatory framework, patent law, and the intersection of these two distinct yet interconnected challenges. Additionally, innovators must be aware of the ways in which intellectual property barriers influence protection of AI-enabled technologies and how to overcome these challenges to bring innovative products to market.

Key Takeaways:

  • The FDA's modernized regulatory framework prioritizes patient safety, ensuring medical technologies are safe, effective, and reliable through rigorous premarket evaluation, postmarket monitoring, and ongoing assessments of risk, transparency, and clinical performance.
  • Patent law incentivizes innovation by granting inventors a limited monopoly in exchange for public disclosure of their invention, subject to requirements of novelty, non-obviousness, and patentable subject matter.
  • FDA oversight and patent law approach AI-enabled technologies from different angles: one safeguards public health, while the other rewards and encourages technological advancement.
  • The FDA's latest guidance on predetermined change control plans and total product lifecycle oversight for AI-enabled medical devices aims to balance innovation with accountability, providing developers with greater regulatory predictability while ensuring adaptive AI technologies remain safe throughout their lifecycle.
  • Patent law challenges arise in the areas of inventorship and subject matter eligibility, particularly with regards to AI contributions to the inventive step and the risk of abstract ideas or laws of nature being deemed unpatentable.
  • Companies must carefully document human involvement to preserve patent rights and ensure that claims emphasize technical improvements and human-directed innovation while preserving flexibility for future product iterations.
  • Best practices for companies developing AI-enabled health care technologies include engaging regulators early, designing PCCPs proactively to ensure efficient updates while staying within FDA-approved parameters, and coordinating patent strategy with regulatory timelines.

Statistics:

  • The FDA's regulatory framework applies to AI-enabled technologies, including machine learning and adaptive algorithms, that pose challenges to traditional FDA frameworks due to their ability to evolve and adapt over time.
  • The FDA's PCCPs enable developers to pre-specify how future software updates will be validated and monitored, avoiding the need for a new submission each time an AI model changes.
  • AI-enabled health care technologies can rely on correlations between biological markers and disease states, but these may face heightened scrutiny under patent law unless tied to novel data processing or system-level improvements.
  • The most effective approach for companies developing AI-enabled health care technologies is to treat regulatory and IP strategies as parallel, coordinated efforts rather than sequential steps.

Sources:

  • [Food and Drug Administration]
  • [Bloomberg Law]
  • [Thaler v. Vidal]
  • [Alice Corp. Pty. v. CLS Bank International]
  • [Mayo Collaborative Services v. Prometheus Labs, Inc.]
  • [Marshall, Gerstein & Borun LLP]